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ABSTRACT  
Objective: To develop and validate stability indicating HPTLC method for determination of Dolasetron mesylate. 
Methods: The chromatographic separation was performed on aluminium plates precoated with silica gel 60 F254
Results: The chromatographic condition gave a compact spot for Dolasetron mesylate at Rf value of 0.65±0.03. Stress testing was performed in 
accordance with international conference on harmonization (ICH) Q1A R2 guidelines. Method was validated as per ICH Q2 R1 guidelines. The 
calibration curve was found to be linear in the concentration range of 100-800 ng/band for Dolasetron mesylate. The limit of detection and 
quantification was found to2.24 ng/band and 6.79 ng/band, respectively.  
 using Methanol: Choloroform: 
Ethyl acetate (7:2:1 v/v/v) as mobile phase followed by densitometric scanning at 280 nm. 
Conclusion: A new sensitive, simple, and stability indicating high performance thin layer chromatographic (HPTLC) method has been developed and 
validated for determination of Dolastron mesylate. The proposed method can be used for routine determination of Dolasetron mesylate stability. 
Keywords: Dolasetron mesylate, HPTLC, Stability indicating method. 
 
INTRODUCTION 
Dolasetron mesylate (fig. 1), is chemically (2α,6α,8α,9aβ)-octahydro-3-
oxo-2,6-methano-2H- quinolizin-8-yl-1H-indole-3-carboxylate mono 
methane sulfonate monohydrate, is an highly specific and selective 
serotonin subtype 3 (5-HT) receptor antagonist, used to treat nausea 
and vomiting in chemotherapy [1, 2]. 
Literature survey revealed that Dolasetron mesylate is official in the 
USP-NF [3] and few methods viz. HPLC [4-7], HPLC-EI-MS and GC-
MS in human plasma [8,9] have been reported for the determination 
of Dolasetron mesylate either as single drug or simultaneous with its 
metabolite. 
To the best of our knowledge, no stability indicating High Performance 
Thin Layer Chromatographic (HPTLC) method has been reported for 
Dolasetron mesylate. The present work involves stress degradation as 
per ICH Q1A (R2) and Q1B [10, 11] for developing new, simple, 
sensitive stability indicating HPTLC method; The method was 
validated as per the ICH guidelines Q2 R1 [12]. 
 
 
Fig. 1: Chemical structure of Dolasetron mesylate 
 
MATERIALS AND METHODS  
Chemicals and reagents  
Dolasetron mesylate was provided as a gift sample by Emcure 
pharmaceutical Pvt. Ltd, Kurkumbh, Pune. Methanol, Chlorofrom, 
Ethyl acetate and all other chemicals used in this study were of AR 
grade purchased from Merck Pvt. Ltd. Mumbai, India. 
Instruments  
Pre-coated silica gel 60F254
Experimental 
aluminium plates (10 x 10 cm, 250 μm 
thickness; Merck, Germany), Linomat-5 sample applicator (Camag, 
Switzerland), twin trough chamber (10 x 10 cm; Camag, 
Switzerland), UV chamber (Camag, Switzerland), TLC scanner 3 
(Camag, Switzerland), winCATS version 1.4.3 software (Camag, 
Switzerland), Photostability chamber (Newtronics NEC103RSPI), 
Shimadzu balance (Model AX-200) were used in the study.  
Preparation of standard solutions  
Standard stock solution of Dolasetron mesylate was prepared by 
dissolving 5 mg of the drug in 10 ml of methanol to get concentration of 
500µg/ml. From the standard stock solution, working standard solution 
was prepared containing 50µg/ml of Dolasetron mesylate. 
Selection of analytical wavelength 
The standard solution Dolasetron mesylate in water was scanned 
over wavelength range 200 to 400 nm by using UV-Visible 
spectrophotometer. Wavelength 280 nm was selected for analysis 
were Dolasetron mesylate showed higher absorbance (fig. 2). 
 
Fig. 2: UV spectrum of Dolasetron mesylate between 200-400 nm 
 
Chromatographic conditions  
TLC plates precoated with silica gel 60 F254, were used as stationary 
phase. TLC plates were pre-washed with methanol and activated at 
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110 °C for 10 min prior to application. The standard solution of 
Dolasetron mesylate, was applied on the pre-coated TLC plate as a band 
with 6 mm width. The chromatographic development was performed by 
using methanol: chloroform: ethyl acetate (7:2:1 v/v/v) as mobile 
phase with 15 minutes chamber saturation time and migration 
distance of 80 mm. Densitometric scanning was performed at 280 
nm. The standard densitogram of Dolasetron mesylate (400 ng/b 
and) are shown in fig. 3. 
 
 
Fig. 3: Densitogram of standard Dolsetron mesylate  
(400 ng/b and) 
 
Stress degradation studies of bulk drug 
Stress degradation studies were carried under a condition of 
acid/base/neutral hydrolysis, oxidation, dry heat and photolysis. For 
each study, samples were prepared, the blank subjected to stress in 
the same manner for the drug solution, working standard solution of 
Dolasetron mesylate subjected to stress degradation. Dry heat and 
photolytic degradation were carried out in a solid state. The 
concentration of degrading reagent and time of exposure was 
optimized to get 10-30 % degradation. 
Acid hydrolysis 
Optimization trial 
Initially, trials were conducted by exposing the sample solution to 
one ml 0.1N HCL for 8 hours and no degradation was observed. 
Optimized trial 
One ml working standard solution of Dolasetron mesylate 
(500μg/ml) was mixed with one ml of 0.1 N HCL (methanolic) and 8 
ml of methanol. Solution was kept for overnight. 8 μl (400 ng/b and) 
of the resulting solution was spotted on TLC plate. Average 86.17% 
of Dolasetron mesylate was recovered with no peak of degradation. 
Alkaline hydrolysis 
Optimization trial 
Initially, trials were conducted using 0.1N NaOH by exposing the 
sample solution for 12 hrs and No degradation were observed. 
Optimized trial 
One ml working standard solution of Dolasetron mesylate (500 
μg/ml) was mixed with one ml of 1 N NaOH (methanolic) and 8 ml of 
methanol. Solution was kept for 2 hr. 8 μl of the resulting solution 
was spotted on TLC plate, and densitogram was developed. Average 
80.31% Dolasetron mesylate was recovered with one peak of 






Fig. 4: I) Densitogram of alkali treated Dolasetron mesylate, II) UV overlay spectrum of Standard drug, alkali treated Dolasetron mesylate, 
Degradation product (D1) 
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Degradation under neutral condition 
One ml working standard solution of Dolasetron mesylate (500 
μg/ml) was mixed with one ml of distilled water and 8 ml of 
methanol. Solution was kept for 48 hrs. 8 μl of the resulting solution 
was spotted on TLC plate. Average 86.84% of Dolasetron mesylate 
was recovered with no peak of degradation in neutral condition. 
Degradation under oxidative condition 
Optimization trial 
Initially, trials were conducted using 10% v/v Hydrogen Peroxide by 
keeping the sample solution for 2 hrs. It was observed that drug get 
degraded completely. 
Optimized trial 
One ml working standard solution of Dolasetron mesylate (500 
μg/ml) was mixed with one ml 10% solution of H 2O 2
Average 87.74% Dolasetron mesylate was recovered with one peak 
of degradation Product (D2) at Rf 0.15 (fig. 5I). Oxidative 
degradation study was performed by increasing exposure time of 
Dolasetron mesylate with 10 % H
 
(methanolic) and 8 ml of methanol. Solution was kept for 30 
minutes. 8 μl (400 ng/b and) of the resulting solution was 
spotted on TLC plate. 
2O2
 
 at 30, 60 and 120 minutes. (fig. 







Fig. 5: I) Densitogram of peroxide treated Dolasetron mesylate, II) Oxidative degradation monitored at 30, 60 and 90 min. III) UV overlay 
spectrum of standard drug, Peroxide treated dolasetron mesylate and Degradation product (D2) 
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Table 1: Oxidative degradation kinetics of Dolasetron mesylate 
S. No. Exposure time to oxidative condition (min) % Recovery  % Degradation 
1 30 87.74 12.26 
2 60  38.53 61.47 
3 120 1.62 98.38 
(Complete degradation) 
 
Degradation under dry heat 
Dry heat studies were performed by keeping drug sample in an oven 
(80 ° C) for a period of 24 hours. Sample was withdrawn, dissolved 
in methanol and diluted to get 500μg/ml. One ml was further diluted 
to get 50 μg/ml solutions of which 8μl volume were spotted on TLC 
plate. Average 71.87 % Dolasetron mesylate was recovered with no 
peak of degradation was observed in dry heat. 
Photo-degradation studies 
Photolytic studies were also carried out by exposure of drug to UV 
light up to 200 watt hours/square meter and subsequently to cool 
white fluorescent light to achieve an illumination of 1200 Lux. Hr. 
Sample were weighed, dissolved and diluted to get 500 μg/ml.  
One ml was further diluted to get 50 μg/ml solutions of which 8 μl 
volumes was spotted on TLC plate. Average 85.48% and 68.69% of 
Dolasetron mesylate was recovered after exposure to UV and 
Fluorescent light respectively with no peak of degradation was 
observed in both. 
Analytical validation parameters 
Specificity 
The specificity of the method was ascertained by analyzing 
standard drug and sample (drug-excipient blend). The spot for 
the drug in a sample was confirmed by comparing the Rf and 
spectra of the spot with that of the standard drug spot. The 
specificity of the method was also ascertained by peak purity 
profiling studies by analyzing the spectrum at peak start, middle 
and at the peak end. The peak purity was determined on Win 






Fig. 6: Calibration curve of Dolasetron mesylate 
 
Linearity and range 
Appropriate volumes were spotted from standard stock solution to 
obtain 100, 200, 400, 500 and 800ng/band respectively. Each 
standard was analysed in five replicates, and peak area was noted. 
The relationship between peak area and concentration was 
established by the simple regression equation method. (fig. 6) 
Accuracy 
To check accuracy in the method, recovery studies were carried out by 
standard drug addition to drug-excipient blends at three different levels 
80%, 100% and 120 %. Basic concentration of sample chosen was 200 
ng/band of standard. The drug concentrations were calculated by using 
regression equation of Dolasetron mesylate (table 2). 
Precision 
The precision to the method was demonstrated by intra-day and inter-
day studies. In the intra-day studies, 3 replicates of 3 standard solutions 
(200, 400 and 500 ng/band) were analyzed in a same day and 
percentage RSD was calculated (table 3). For the inter-day variation 
studies, 3 standard solutions (200, 400 and 500 ng/band) were analyzed 
on three consecutive days and percentage RSD was calculated (table 4). 
LOD and LOQ 
The LOD (limit of detection) and LOQ (limit if quantification) of 
Dolasetron mesylate were estimated from the standard deviation of 
the response and the slope to the calibration curve. LOD and LOQ 
were found to be 2.24 ng/band and 6.79 ng/band respectively. 
Robustness 
The robustness of the method was studied, during method 
development, by small but deliberate variations in chamber 
saturation time (13, 17 min), change in mobile phase composition, 
time from application to development (30, 120 min), and time from 
development to scanning (30, 120 min). One factor at a time was 
changed at a concentration level of 400ng/band to study the effect 
on peak area of drug (table 5). 
 
Table 2: Determination of accuracy for Dolasetron mesylate 
Level (%) Concentration (ng/band) Avg. area % Recovery % RSD 
Sample conc. Amount added 
80% 200 160 3058.4 99.14 0.78 
100% 200 200 3358 98.71 1.02 
120% 200 240 3648.5 98.08 1.43 
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Table 3: Intra-day precision 
S. No. Concentration (ng/band) Intraday mean area* % recovery SD % RSD 
1 200 1862.93 100.57 10.92 0.52 
2 400 3751.33 101.43 14.83 0.39 
3 500 4750.06 102.78 13.18 0.27 
* Average of 3 determinations 
 
Table 4: Inter-day precision 
S. No. Concentration (ng/band) Inter day mean area* % recovery SD % RSD 
1 200 1899.33 102.54 11.12 0.58 
2 400 3745.53 101.27 13.75 0.36 
3 500 4730.76 102.30 51.38 1.08 
* Average of 3 determinations 
 
Table 5: Robustness study of Dolasetron mesylate 
S. No. Parameters Robust condition % RSD 
1.  Chamber saturation time(15 min)±2 min. 13 min 0.71 
17 min 0.52 
2.  Mobile phase compositionMethanol: Chloroform: Et. 
acetate: (7:2:1 v/v)±0.2 Methanol 
Methanol: Chloroform: Et acetate (7.2: 2:1 v/v) 1.2 
Methanol: Chloroform: Et acetate (6.8: 2:1 v/v) 0.62 
3.  Time from Application to development (immediate) After 30 min. 1.25 
After 2 hrs 1.68 
4.  Time from Development to Scanning(immediate) After 30 min. 0.82 
After 2 hrs 1.32 
 
RESULTS AND DISCUSSION 
Optimization of mobile phase 
Method development for Dolasetron mesylate was started with the 
development of densitogram using neat solvents and combinations of 
Methanol, Chloroform, Ethyl acetate, and Toluene in different ratios. 
Methanol: Chloroform: Ethyl acetate in the ratio of (7:2:1 v/v/v) was 
selected as the mobile phase for Dolasetron mesylate, which 
resulted in acceptable peak parameters. The Rf found to be 
0.65±0.03 for Dolasetron mesylate. 
Stress degradation  
Drug was subjected to various forced degradation conditions. 
The conditions of stress were optimized with respect to the 
strength of the reagent and exposure period so as to achieve 
degradation in the range of 10 to 30%. During optimization of 
degradation conditions, if the higher percentage of degradation 
was observed, milder conditions were used with lesser duration 
of exposure. If percent degradation is high, there are chances of 
formation of secondary products.  
This was carefully avoided. Although percent assay reduced 
under all conditions; the separate peak for degradation product 
was observed only under base and oxidative conditions. In order 
to make the product peaks easier to locate in other conditions, 
10 times higher concentrations was spotted. But no product 
peak could be located. The degradation under oxidative stress is 
being investigated further. Summary of stress degradation 
results is given in table 6. 
  
Table 6: Summary of stress degradation study of Dolasetron mesylate 
S. No. Stress degradation condition % Recovery % Degradation Rf of degradation product 
1 Acid (0.1 N HCl,kept for overnight) 86.17 13.83 - 
2 Base (1N NaOH,kept for 90 mins) 80.31 19.69 0.14 
3 Water(Kept for 48 hrs.) 86.84 13.16 - 
4 H2O2 87.74 10%(Kept for 30 min.) 12.26 0.15 
5 Heat dry(80 °C, 24 hrs.) 71.87 28.13 - 
6. Photo stability[UV, 200 watt hrs/square 








Method validation  
The method validation results were satisfactory as per ICH Q2R1 
guidelines. The peak areas were found to be linear over the 
concentration range 100–800 ng/band with a correlation co-
efficient of 0.999. Method specificity can be proved using “Peak 
Purity” parameter in WinCats software of HPTLC. There is a 
provision to compare the UV spectrum at the start, middle and end 
of any peak. The percent matching indicates peak purity. Peak purity 
results greater than 0.999 indicate that peak is homogeneous in all 
stress conditions tested.  The unaffected assay of drug in the blend 
confirms the non-interference by any excipient. Inter and Intraday 
precision were less than 2%. Percent recovery in accuracy study was 
within the limit of 98 to 102%. The results of validation are 
summarized in table 7. 
Thus the optimized HPTLC method for Dolasetron is based on use of 
simple ternary mixture of organic solvents. The method is found to 
be sensitive with limit of quantitation less than 10 ng/band. The 
drug was found to be prone to oxidation and alkali catlaysed 
hydrolysis. The oxidative degradation was found to be faster than 
hydrolytic. The degradation products observed under these 
conditions were well resolved from the drug peak.  
The spectral purity of drug peak indicates specificity of the method. 
Dolasetron was found to be photolabile. The peak area was found to 
reduce upon exposure to ultraviolet and fluorescent light as per ICH 
Q1B guidelines. But the peak for the product of degradation was not 
noticed. The peak purity of drug peak is maintained even in 
photodegraded sample. Thus the developed method is stability 
indicating. 
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Table 7: Summary of validation parameters 
S. No.  Validation parameter Results 
1.  Linearity  Y= 9.23X+6.330R2 = 0.999 
2.  Range  100-800 ng/band 
3.  Precision  (%RSD) 
A) Intraday precision  0.39 
B) Interday precision  0.67 
4.  Accuracy  % Recovery  
80%  99.14 
100%  98.71 
120%  98.08 
5.  LOD  2.24 ng/band  
6.  LOQ  6.79 ng/band 
7.  Specificity  Specific  
8.  Robustness  Robust  
 
CONCLUSION  
The developed method is stability indicating where well resolved 
peaks were observed for analyte and degradation product. The 
method is specific, accurate, precise, robust and can be used for 
routine quality control as well as assessing the stability of 
Dolasetron mesylate in bulk. 
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